Table 1.
Baseline Patient Demographic and Clinical Characteristics
| Total patients | EBV<103 | 103≤EBV<105 | EBV≥105 | |
|---|---|---|---|---|
| n=830 | n=391(47.1%) | n=357(43%) | n=82(9.9%) | |
| Age (years) | ||||
| median | 45(13-78) | 44(13-76) | 45(13-77) | 45(24-78) |
| Sex | ||||
| male | 590(71.1%) | 283(72.4%) | 251(70.3%) | 56(68.3%) |
| female | 240(28.9%) | 108(27.6%) | 106(29.7%) | 26(31.7%) |
| Tumor stage | ||||
| T1 | 60(7.2%) | 42(10.7%) | 17(4.8%) | 1(1.2%) |
| T2 | 187(22.5%) | 116(29.7%) | 58(16.2%) | 13(15.9%) |
| T3 | 382(46%) | 166(42.5%) | 173(48.5%) | 43(52.4%) |
| T4 | 201(24.3%) | 67(17.1%) | 109(30.5%) | 25(30.5%) |
| Node stage | ||||
| N0 | 100(12%) | 76(19.4%) | 21(5.9%) | 3(3.7%) |
| N1 | 343(41.3%) | 189(48.3%) | 134(37.5%) | 20(24.4%) |
| N2 | 320(38.6%) | 112(28.6%) | 171(47.9%) | 37(45.1%) |
| N3 | 67(8.1) | 14(3.6%) | 31(8.7%) | 22(26.8%) |
| TNM stage | ||||
| I | 18(2.2%) | 17(4.3%) | 1(0.3%) | 0(0%) |
| II | 129(15.5%) | 103(26.3%) | 23(6.4%) | 3(3.7%) |
| III | 423(51%) | 192(49.1%) | 196(54.9%) | 35(42.7%) |
| IVA | 260(31.3%) | 79(20.3%) | 137(38.4%) | 44(53.6%) |
| FU (months) | ||||
| median | 84(4-112) | |||